Key Highlights

  • Phibro Animal Health (NASDAQ: PAHC) appoints Dani Bendheim as CEO and President with an $850,000 annual base salary.
  • Bendheim receives 300,000 restricted stock units (RSUs) tied to stock performance, vesting in increments based on a 90-day average share price.
  • Vesting accelerates to 100% if the 90-day average share price reaches $100.

Phibro Animal Health (NASDAQ: PAHC) has appointed Dani Bendheim as its new Chief Executive Officer and President, marking a leadership transition. The move includes a structured compensation package with performance-linked incentives, reflecting the company’s focus on aligning executive pay with shareholder returns.

Leadership Transition Timeline

Bendheim will assume his role following board approval. His appointment follows a formal employment agreement outlining salary, bonuses, and equity awards. The terms position him to drive growth in the animal health sector amid evolving market demands.

Compensation Breakdown

Under the agreement, Bendheim’s base salary is set at $850,000 annually. He is also eligible for an annual discretionary bonus targeting 50% of his base salary.

Equity Incentives

The board granted Bendheim 300,000 RSUs, subject to performance-based vesting conditions. These units will vest in increments of 25% tied to the company’s 90-day average stock price, with vesting beginning at a share price of $70 and full vesting at $100 or above.

Vesting Conditions

If the 90-day average share price falls below $70, the vesting will be affected. The maximum vesting percentage is 100%, achievable if the stock price meets or exceeds $100.

Termination Provisions

In the event of termination, Bendheim is entitled to certain benefits, including continued base salary under specific conditions.

Change-in-Control Protections

The RSU agreement includes provisions for a change in control. If the company faces a qualifying event, all unvested RSUs will vest immediately at 100%.

Regulatory Filings

Details of the employment and RSU agreements will be disclosed in Phibro Animal Health’s regulatory filings, providing full transparency on the terms.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.